PipelineReview.com1d
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME ...
PipelineReview.com2d
Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor
CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...
PipelineReview.com2d
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiRâ„¢ Trial for Myotonic Dystrophy Type 1 (DM1)
“ATX-01 is a very unique molecule – it was discovered and developed entirely in-house by ARTHEx scientists through years of engineering and execution, and we are excited about the potential of its ...
PipelineReview.com2d
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling ...
PipelineReview.com2d
Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative
At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone ...
PipelineReview.com5d
IsomAb Announces Nomination of Development Candidate for Peripheral Arterial Disease and Strategic Collaboration with Pfizer
ISM-001 is a potential first-in-class antibody that may lead to a new treatment pathway for patients with peripheral arterial ...
PipelineReview.com3d
U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson’s Disease
NORTH CHICAGO, IL, USA I October 17, 2024 I AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VYALEVâ„¢ ...
PipelineReview.com3d
Clarametyx Biosciences Announces Progress on Study of Antibody Therapy CMTX-101 for Infections Associated With Cystic Fibrosis
Following successful Phase 1b completion, Clarametyx is initiating the Phase 2a portion to assess CMTX-101 as an adjunct to standard of care for chronic ...